Radiopharmaceuticals and their applications in medicine
Open accessThe DOI matches its Crossref record; 454 of the 454 references it cites were found in a registry or an index.
Abstract
Radiopharmaceuticals involve the local delivery of radionuclides to targeted lesions for the diagnosis and treatment of multiple diseases. Radiopharmaceutical therapy, which directly causes systematic and irreparable damage to targeted cells, has attracted increasing attention in the treatment of refractory diseases that are not sensitive to current therapies. As the Food and Drug Administration (FDA) approvals of [177 Lu]Lu-DOTA-TATE, [177 Lu]Lu-PSMA-617 and their complementary diagnostic agents, namely, [68 Ga]Ga-DOTA-TATE and [68 Ga]Ga-PSMA-11, targeted radiopharmaceutical-based theranostics (radiotheranostics) are being increasingly implemented in clinical practice in oncology, which lead to a new era of radiopharmaceuticals. The new generation of radiopharmaceuticals utilizes a targeting vector to achieve the accurate delivery of radionuclides to lesions and avoid off-target deposition, making it possible to improve the efficiency and biosafety of tumour diagnosis and therapy. Numerous studies have focused on developing novel radiopharmaceuticals targeting a broader range of disease targets, demonstrating remarkable in vivo performance. These include high tumor uptake, prolonged retention time, and favorable pharmacokinetic properties that align with clinical standards. While radiotheranostics have been widely applied in tumor diagnosis and therapy, their applications are now expanding to neurodegenerative diseases, cardiovascular diseases, and inflammation. Furthermore, radiotheranostic-empowered precision medicine is revolutionizing the cancer treatment paradigm. Diagnostic radiopharmaceuticals play a pivotal role in patient stratification and treatment planning, leading to improved therapeutic outcomes in targeted radionuclide therapy. This review offers a comprehensive overview of the evolution of radiopharmaceuticals, including both FDA-approved and clinically investigated agents, and explores the mechanisms of cell death induced by radiopharmaceuticals. It emphasizes the significance and future prospects of theranostic-based radiopharmaceuticals in advancing precision medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–454 of 454
Evaluation of l-1-[18F]Fluoroethyl-Tryptophan for PET Imaging of Cancer
Xin, Y., Gao, X., Liu, L., Ge, W., Jain, M., & Cai, H. (2019) · Molecular Imaging and Biology · doi:10.1007/s11307-019-01327-4 · Cited by 23
Self-citationImmuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054
Tavaré, R., Danton, M. A., Giurleo, J. T., Makonnen, S., Hickey, C., Arnold, T. C., Kelly, M. P., Fredriksson, F., Bruestle, K., Hermann, A., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0405 · Cited by 23
DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy
Obata, H., Ogawa, M., & Zalutsky, M. R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071926 · Cited by 23
Wang, L., Yui, J., Wang, Q., Zhang, Y., Mori, W., Shimoda, Y., Fujinaga, M., Kumata, K., Yamasaki, T., Hatori, A., et al. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00248 · Cited by 22
Using α radiation to boost cancer immunity?
Gorin, J., Guilloux, Y., Morgenstern, A., Chérel, M., Davodeau, F., & Gaschet, J. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954925 · Cited by 22
Ito, H., Shimada, H., Shinotoh, H., Takano, H., Sasaki, T., Nogami, T., Suzuki, M., Nagashima, T., Takahata, K., Seki, C., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.133793 · Cited by 22
Yousefi, B. H., Manook, A., Grimmer, T., Arzberger, T., von Reutern, B., Henriksen, G., Drzezga, A. E., Förster, S., Schwaiger, M., & Wester, H. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn5001827 · Cited by 22
In vivo exploration of synaptic projections in frontotemporal dementia
Salmon, E., Bahri, M. A., Plenevaux, A., Becker, G., Seret, A., Delhaye, E., Degueldre, C., Balteau, E., Lemaire, C., Luxen, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95499-1 · Cited by 21
Radhakrishnan, R., Worhunsky, P. D., Zheng, M., Najafzadeh, S., Gallezot, J., Planeta, B. M., Henry, S. E., Nabulsi, N., Ranganathan, M., Skosnik, P. D., et al. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119674 · Cited by 20
Preclinical Characterization of the Tau PET Tracer [18F]SNFT-1: Comparison of Tau PET Tracers
Harada, R., Lerdsirisuk, P., Shimizu, Y., Yokoyama, Y., Du, Y., Kudo, K., Ezura, M., Ishikawa, Y., Iwata, R., Shidahara, M., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265593 · Cited by 20
SPECT Imaging of Hepatocellular Carcinoma Detection by the GPC3 Receptor
Xu, H., Tang, Y., Zhao, Y., Wang, F., Gao, X., Deng, D., & Gu, Y. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00060 · Cited by 19
Self-citationChen, Z., Mori, W., Rong, J., Schafroth, M. A., Shao, T., Van, R. S., Ogasawara, D., Yamasaki, T., Hiraishi, A., Hatori, A., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.01.021 · Cited by 18
Self-citationKagitani‐Shimono, K., Kato, H., Soeda, F., Iwatani, Y., Mukai, M., Ogawa, K., Tominaga, K., Nabatame, S., & Taniike, M. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103288 · Cited by 18
Time course of neuroinflammation after human stroke – a pilot study using co-registered PET and MRI
D’Anna, L., Searle, G. E., Harvey, K., Matthews, P. M., & Veltkamp, R. C. (2023) · BMC Neurology · doi:10.1186/s12883-023-03178-7 · Cited by 18
Drake, L. R., Wu, Y., Naganawa, M., Asch, R., Zheng, C., Najafzadeh, S., Pracitto, R., Lindemann, M., Li, S., Ropchan, J., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266470 · Cited by 18
Dalm, S. U., Duan, H., & Iagaru, A. H. (2024) · PET Clinics · doi:10.1016/j.cpet.2024.03.004 · Cited by 18
Fu, J., Xi, H., Cai, S., Peng, Y., Liu, Q., Qiu, L., & Lin, J. (2024) · ACS Nano · doi:10.1021/acsnano.4c01157 · Cited by 18
Davies, A. J. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.4.577 · Cited by 17
Jia, H., Cai, Z., Holden, D., He, Y., Lin, S.-F., Li, S., Baum, E. J., Shirali, A. R., Kapinos, M., Gao, H., et al. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00171 · Cited by 17
Guo, W., Wen, X., Chen, Y., Zhao, T., Liu, J., Tao, Y., Fu, H., Wang, H., Xu, W., Pang, Y., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.05.022 · Cited by 17
Self-citationAn Overview of Nuclear Imaging
ZANZONICO, P. B. (2019) · Springer eBooks · doi:10.1007/978-3-032-26476-3_6 · Cited by 16
Takahata, K., Seki, C., Kimura, Y., Kubota, M., Ichise, M., Sano, Y., Yamamoto, Y., Tagai, K., Shimada, H., Kitamura, S., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05671-y · Cited by 16
In vivo clinical molecular imaging of T cell activity
Cheng, X., Shen, J., Xu, J., Zhu, J., Xu, P., Wang, Y., & Gao, M. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.10.002 · Cited by 16
Current development of sigma-2 receptor radioligands as potential tumor imaging agents
Shaghaghi, Z., Alvandi, M., Ghanbarimasir, Z., Farzipour, S., & Emami, S. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105163 · Cited by 15
Alsaid, H., Cheng, S., Bi, M., Xie, F., Rambo, M. V., Skedzielewski, T., Hoang, B. Q., Mohanan, S., Comroe, D., Gehman, A., et al. (2022) · Molecular Imaging and Biology · doi:10.1007/s11307-022-01781-7 · Cited by 15
Preclinical and clinical study on [18F]DRKXH1: a novel β-amyloid PET tracer for Alzheimer’s disease
Xu, M., Guo, J., Gu, J., Zhang, L., Liu, Z., Ding, L., Fu, H., Ma, Y., Liang, S., & Wang, H. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05421-0 · Cited by 14
Wang, Z., Zhao, C., Ding, J., Chen, Y., Liu, J., Hou, X., Kong, X., Dong, B., Yang, Z., & Zhu, H. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00165 · Cited by 14
Dierks, A., Gäble, A., Rinscheid, A., Wienand, G., Pfob, C. H., Kircher, M., Enke, J. S., Janzen, T., Patt, M., Trepel, M., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266741 · Cited by 14
Dietz, M., Kamani, C. H., Dunet, V., Fournier, S., Rubimbura, V., Dardel, N. T., Schaefer, A., Jreige, M., Boughdad, S., Lalonde, M. N., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.887508 · Cited by 13
Evaluation of the α-synuclein PET radiotracer (d3)-[11C]MODAG-001 in pigs
Raval, N. R., Madsen, C. A., Shalgunov, V., Nasser, A., Battisti, U. M., Beaman, E. E., Juhl, M., Jørgensen, L. M., Herth, M. M., Hansen, H. D., et al. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.08.001 · Cited by 13
Baglini, E., Poggetti, V., Cavallini, C., Petroni, D., Forini, F., Nicolini, G., Barresi, E., Salerno, S., Costa, B., Iozzo, P., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01716 · Cited by 13
Li, D., Ding, L., Chen, Y., Wang, Z., Zeng, Z., Ma, X., Huang, H., Li, H., Qian, X., Yang, Z., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116134 · Cited by 13
Hong, J. S., Telu, S., Zhang, Y., Miller, W. H., Shetty, H. U., Morse, C. L., & Pike, V. W. (2021) · Nature Protocols · doi:10.1038/s41596-021-00584-4 · Cited by 12
Hattori, Y., Seki, C., Maeda, J., Nagai, Y., Aoyama, K., Zhang, M., Minamimoto, T., Koike, T., & Higuchi, M. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x211058285 · Cited by 12
Imaging the brain’s immune response to alcohol with [11C]PBR28 TSPO Positron Emission Tomography
Raval, N. R., Angarita, G. A., Matuskey, D., Miller, R., Drake, L. R., Kapinos, M., Nabulsi, N., Huang, Y. H., Carson, R. E., O’Malley, S. S., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02198-6 · Cited by 12
Chen, C., Bando, K., Ashino, H., Taguchi, K., Shiraishi, H., Shima, K., Fujimoto, O., Kitamura, C., Morimoto, Y., Kasahara, H., et al. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.08.036 · Cited by 11
Leonte, R. A., Chilug, L., Serban, R. M., Mustăciosu, C. C., Raicu, A., Manda, G., & Niculae, D. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040506 · Cited by 11
Watts, J. J., Guma, E., Chavez, S., Tyndale, R. F., Ross, R. A., Houle, S., Wilson, A. A., Chakravarty, M. M., Rusjan, P., & Mizrahi, R. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01384-4 · Cited by 11
Zhang, Y., Deshane, J. S., Yang, E. S.-H., & Larimer, B. M. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.12.047 · Cited by 11
Mishra, A., Carrascal-Miniño, A., Kim, J., & de Rosales, R. T. M. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00039k · Cited by 10
Quantitative kinetic analysis of PET amyloid imaging agents [11C]BF227 and [18F]FACT in human brain
Shidahara, M., Watabe, H., Tashiro, M., Okamura, N., Furumoto, S., Watanuki, S., Furukawa, K., Arakawa, Y., Funaki, Y., Iwata, R., et al. (2015) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2015.05.001 · Cited by 9
Orlovskaya, V. V., Fedorova, O. S., Viktorov, N. B., Ваулина, Д. Д., & Красикова, Р. Н. (2023) · Molecules · doi:10.3390/molecules28062732 · Cited by 9
Yang, Z., Banks, S. J., Ritter, A. R., Cummings, J. L., Sreenivasan, K. R., Kinney, J. W., Caldwell, J. K., Wong, C. G., Miller, J. B., & Cordes, D. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230631 · Cited by 9
Wu, Y., Sun, X., Zhang, B., Zhang, S., Wang, X., Sun, Z., Liu, R., Zhang, M., & Hu, K. (2023) · PubMed Central · Cited by 9
Self-citationEmerging targets for positron emission tomography imaging in proteinopathies
Chassé, M., & Vasdev, N. (2024) · npj Imaging · doi:10.1038/s44303-024-00032-4 · Cited by 9
Synthesis of [18F] fluorine-labeled K-2 derivatives as radiotracers for AMPA receptors
Arisawa, T., Kimura, K., Miyazaki, T., Takada, Y., Nakajima, W., Ota, W., Ichijo, S., Sano, A., Hirao, Y., Kurita, J.-I., et al. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.04.009 · Cited by 8
Imaging of Transmembrane AMPA Receptor Regulatory Proteins by Positron Emission Tomography
Yu, Q., Kumata, K., Rong, J., Chen, Z., Yamasaki, T., Chen, J., Xiao, Z., Ishii, H., Hiraishi, A., Shao, T., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00377 · Cited by 8
Self-citationYan, X., Siméon, F. G., Liow, J., Morse, C. L., Santamaria, J. A. M., Jenkins, M. D., Manly, L. S., Buskirk, M. G. V., Zoghbi, S. S., Pike, V. W., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06270-9 · Cited by 8
Arakawa, R., Takano, A., Nag, S., Jia, Z., Amini, N., Maresca, K. P., Zhang, L., Keliher, E. J., Butler, C. R., Piro, J. R., et al. (2022) · EJNMMI Research · doi:10.1186/s13550-022-00882-2 · Cited by 7
Manos‐Turvey, A., Becker, G., Francotte, P., Navacerrada, M. E. S., Luxen, A., Pirotte, B., Plenevaux, A., & Lemaire, C. F. (2019) · ChemMedChem · doi:10.1002/cmdc.201800816 · Cited by 6
Advances in Understanding the Pathogenesis of Inflammatory Bowel Disease
Kotlyar, D. S., Blonski, W. C., & Lichtenstein, G. R. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374145-5.00338-7 · Cited by 3
From “Azalla” to Anandamide: Distilling the Therapeutic Potential of Cannabinoids
Radhakrishnan, R., & Ross, D. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.11.017 · Cited by 3
Kobayashi, R., Nakamura, T., Naganuma, F., Harada, R., Morioka, D., Kanoto, M., Furumoto, S., Kudo, Y., Kabasawa, T., Otani, K., et al. (2023) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlad018 · Cited by 3
Visualization of Thromboinflammation by 18F-DPA-714 PET in a Stroke Patient
Lin, Q., Wang, Y., Zhao, W., & Yao, S. (2023) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004803 · Cited by 3
Metadata
- Authors
- Zhang, S., Wang, X., Gao, X., Chen, X., Li, L., Li, G., Liu, C., Miao, Y., Wang, R., & Hu, K.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2025-01-03
- Volume
- 10
- Issue
- 1
- Pages
- 1-1
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4406003699
- Cited by
- 284
- References
- 454
- FWCI
- 151.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.